Additional Information

Description

Cinvanti 130 mg/18 mL Vial (aprepitant) is an FDA-approved injectable emulsion indicated for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy (HEC and MEC). It is a substance P/neurokinin-1 (NK1) receptor antagonist used in adults in combination with other antiemetic agents.

Cinvanti is effective in preventing both acute and delayed chemotherapy-induced nausea and vomiting (CINV), offering two administration regimens: a single-dose regimen for HEC and a 3-day regimen for MEC. This medication provides a crucial role in improving the quality of life for patients undergoing repeated cycles of chemotherapy.

The mechanism of action involves blocking the interaction of substance P with the NK1 receptor in the brain, which is a key pathway in the induction of nausea and vomiting. Administered intravenously, Cinvanti is well-suited for patients unable to tolerate oral medications. It has shown a safety profile similar to oral aprepitant and offers a convenient alternative with comparable efficacy.

The most common adverse reactions include headache, fatigue, and, occasionally, infusion site reactions. Cinvanti is administered as either a 2-minute injection or a 30-minute infusion, both demonstrating similar safety profiles. Its ability to prevent chemotherapy-induced nausea and vomiting makes it an integral component of supportive care for cancer patients.